RASSF10 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 3
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, E |
---|---|
Primary Accession | A6NK89 |
Other Accession | NP_001073990.2 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 56900 Da |
Antigen Region | 230-259 aa |
Gene ID | 644943 |
---|---|
Other Names | Ras association domain-containing protein 10, RASSF10 |
Target/Specificity | This RASSF10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 230-259 amino acids from the Central region of human RASSF10. |
Dilution | WB~~1:1000 IHC-P~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | RASSF10 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RASSF10 |
---|---|
Function | Plays an important role in regulating embryonic neurogenesis. |
Cellular Location | Cytoplasm, cytosol. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole. Note=During interphase, predominantly cytoplasmic, although some nuclear staining in several tumor cell contexts. During prophase, observed at developing centrosomes. Displays persistent localization with centrosomally radiating microtubule bundles until late telophase. Associates with spindle poles particularly during metaphase and anaphase before relocating back to the cytoplasm |
Tissue Location | Expressed in brain. Tends to be down-regulated in astrocytic gliomas due to promoter methylation. Methylation occurs early in gliomagenesis and the extent of methylation parallels with higher glioma grades, so that methylation is observed in close to 70% WHO grade IV primary glioblastomas, but not in grade I astrocytomas |
Provided below are standard protocols that you may find useful for product applications.
References
Schagdarsurengin, U., et al. Epigenetics 4(8):571-576(2009)
Hesson, L.B., et al. Mol. Cancer 8, 42 (2009) :
Sherwood, V., et al. Mol. Biol. Cell 19(4):1772-1782(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.